You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Daily and Localized NSAID Sonophoresis for Symptomatic Treatment of Knee Osteoarthritis
SBC: ZETROZ SYSTEMS LLC Topic: RProject Summary: Osteoarthritis (OA) is the most common type of arthritis, affecting over 30 million adults in the United States in 2015 and represents over 25% of medical office visits according to the Centers for Disease Control and Prevention and the National Institutes of Health. Over 40% of individuals over 65 have symptomatic OA and reduced mobility due to the disease. OA pain is often mitig ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
An Integrated CT-based Image-Guided Neurosurgical System
SBC: Xoran Technologies LLC Topic: 102An Integrated CT-based Image-Guided Neurosurgical System In this SBIR Phase IIb proposal Xoran intends to commercialize a compact and affordable, yet highly- functional, system to provide real time image updates and navigation guidance in support of minimally invasive cranial and spinal neurosurgical procedures. The effort builds on previously developed compact and portable flat-panel Computed Tom ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Commercial Readiness for Direct-to-Digital Pathology
SBC: APPLIKATE TECHNOLOGIES, INC. Topic: NCIAbstract Project Summary Applikate Technologies has developed Clearing Histology with Multiphoton Microscopy (CHiMP), a novel tissue processing and imaging platform that provides direct-to-digital images from intact pathology tissue specimens, such as biopsies, without the need for wax embedding, slicing, or scanning of slides. The application of this technology to cancer diagnosis will reduce err ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of SP-A Derived Peptidomimetics for the Treatment of Asthma- Phase II
SBC: RaeSedo, LLC Topic: NHLBICurrent treatments for asthma, while reducing exacerbations in a subset of patients by focusing on airway inflammation, do not eliminate them. Asthma exacerbations are a significant cause of morbidity and mortality in asthma as they can lead to airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and lost productivi ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Phosphodiesterase-4B (PDE4B) Inhibitors for Alzheimer's Disease
SBC: Tetra Discovery Partners, Inc. Topic: 101Under the parent grantTetra Discovery Partners is developing phosphodiesteraseBPDE Ballosteric inhibitors as a treatment for major depressive disorderUniquelythe Tetra drug will address inflammation as a contributor to depressionThis is a new mechanism of action for an antidepressant drug which should prove complimentary to current therapeuticsThe company estimates thatof patients with depression ...
SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Producing Polyclonal Human Antibodies to Anthrax
SBC: HEMATECH, LLC Topic: N/ADESCRIPTION (provided by applicant): Anthrax is a high risk bioterrorist threat. Despite high dose antibiotic therapy, several deaths occurred following the 2001 mail attack. Passive immunization with anti-anthrax immunoglobulins, in combination with
SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
The Sustainable Heartland Accelerator Regional Partnership (SHARP) Hub
SBC: BBC ENTREPRENEURIAL TRAINING & CONSULTING LLC Topic: 500Project Summary/Abstract Despite the investment of billions of dollars in biomedical research each year from NIH, barriers remain in effectively translating basic science discoveries from academia to commercial products that benefit patients. These barriers include a funding gap between basic research and commercial developments, a lack of knowledge by innovators on how to bring products to market ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Commercialization Readiness Program (CRP) for Bioabsorbable Magnesium (Mg) Implants for Craniomaxillofacial Surgical Systems
SBC: NANOMAG LLC Topic: NIDCRNIH 19-333 – Project Summary nanoMAG has invented a bioabsorbable magnesium metal alloy, BioMg ®250, for craniomaxillofacial trauma and reconstruction fixation (1,2,3). This novel and proprietary alloy is intended to obviate the cost and pain of secondary removal surgery, required for 20% of patients with existing absorbable and non-absorbable implants. BioMg 250’s biocompatible chemistry and ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Clinical Evaluation of NoGo Trap Therapy in Chronic SCI
SBC: RENETX BIO, INC. Topic: NINDSSummary Approximately 300,000 patients suffer from persistent neurological impairment due to chronic spinal cord injury (SCI) in the United States. Currently, there are no FDA-approved drugs to promote neurologic recovery in patients suffering from the life-long, profound impairments due to chronic SCI. An effective neurorestorative therapy would significantly improve the ability of patients to co ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV
SBC: Carogen Corporation Topic: 300The ultimate objective of this SBIR project is to develop an immunotherapy based on our recently patented virus-like vesicle (VLV) platform for the treatment of chronic hepatitis B (CHB). The goal of this project is to complete preclinical studies and product development of the CARG-201 vaccine. We have designed this vector to achieve a functional cure in CHB patients, characterized by a sustained ...
SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health